A cancer-associated fibroblast subtypes-based signature enables the evaluation of immunotherapy response and prognosis in bladder cancer

Yiming Qin; Xiongbing Zu; Yin Li; Ying Han; Jun Tan; Changjing Cai; Edward Shen; Ping Liu; Ganlu Deng; Ziyang Feng; Wantao Wu; Yinghui Peng; Yongting Liu; Jiayao Ma; Shan Zeng; Yihong Chen; Hong Shen

iScience (Sep 2023)

A cancer-associated fibroblast subtypes-based signature enables the evaluation of immunotherapy response and prognosis in bladder cancer

Yiming Qin,
Xiongbing Zu,
Yin Li,
Ying Han,
Jun Tan,
Changjing Cai,
Edward Shen,
Ping Liu,
Ganlu Deng,
Ziyang Feng,
Wantao Wu,
Yinghui Peng,
Yongting Liu,
Jiayao Ma,
Shan Zeng,
Yihong Chen,
Hong Shen

Affiliations

Yiming Qin: Department of Spine Surgery and Orthopaedics, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China
Xiongbing Zu: National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China
Yin Li: Department of Oncology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China
Ying Han: Department of Oncology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China
Jun Tan: Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China
Changjing Cai: Department of Oncology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China
Edward Shen: Department of Life Science, McMaster University, Hamilton L8S 4L8, ON, Canada
Ping Liu: Department of Oncology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China
Ganlu Deng: Department of Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530022, Guangxi, China
Ziyang Feng: Department of Oncology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China
Wantao Wu: Department of Oncology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China
Yinghui Peng: Department of Oncology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China
Yongting Liu: Department of Oncology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China
Jiayao Ma: Department of Oncology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China
Shan Zeng: Department of Oncology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China
Yihong Chen: Department of Oncology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China; Corresponding author
Hong Shen: Department of Oncology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China; Corresponding author

Journal volume & issue: Vol. 26, no. 9
p. 107722

Abstract

Read online

Summary: Bladder cancer (BLCA) is one of the most prevalent and heterogeneous urinary malignant tumors. Previous researches have reported a significant association between cancer-associated fibroblasts (CAFs) and poor prognosis of tumor patients. However, uncertainty surrounds the role of CAFs in the BLCA tumor microenvironment, necessitating further investigation into the CAFs-related gene signatures in BLCA. In this study, we identified three CAF subtypes in BLCA according to single-cell RNA-seq data and constructed CAFs-related risk score (CRRS) by screening 102,714 signatures. The survival analysis, ROC curves, and nomogram suggested that CRRS was a valuable predictor in 2,042 patients from 9 available public datasets and Xiangya real-world cohort. We further revealed the significant correlation between CRRS and clinicopathological characteristics, genome alterations, and epithelial-mesenchymal transition (EMT). A high CRRS indicated a non-inflamed phenotype and a lower remission rate of immunotherapy in BLCA. In conclusion, the CRRS had the potential to predict the prognosis and immunotherapy response of BLCA patients.

Published in iScience

ISSN: 2589-0042 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Science
Website: http://www.cell.com/iscience/home

About the journal

Abstract

Keywords